🇮🇳 India Pharma Q3 Growth Drivers and Key Players Indian pharmaceutical companies project a **mixed performance** for the third quarter. Growth will be primarily fueled by strong **domestic sales** and the performance of new, high-value **specialty drugs**. The **US generics** segment is also set to benefit from the launch of new products. --- Segment Outlook **Contract services** and the **Active Pharmaceutical Ingredients (APIs)** segment are expected to register **moderate gains** during this period. **Divi's Laboratories** stands out, anticipating especially robust growth in its **custom synthesis** business. --- Player Performance **Sun Pharma** and **Lupin** are positioned to be the **market leaders** for the quarter. Conversely, major players **Cipla** and **Dr Reddy's Laboratories** are facing challenges, anticipating **softer sales** within the crucial US market.